Literature DB >> 7600586

Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract.

C M Lehr1.   

Abstract

For the efficient delivery of peptides, proteins, and other biopharmaceuticals by nonparenteral routes, in particular via the gastrointestinal, or GI, tract, novel concepts are needed to overcome significant enzymatic and diffusional barriers. In this context, bioadhesion technologies offer some new perspectives. The original idea of oral bioadhesive drug delivery systems was to prolong and/or to intensify the contact between controlled-release dosage forms and the stomach or gut mucosa. However, the results obtained during the past decade using existing pharmaceutical polymers for such purposes were rather disappointing. The encountered difficulties were mainly related to the physiological peculiarities of GI mucus. Nevertheless, research in this area has also shed new light on the potential of mucoadhesive polymers. First, one important class of mucoadhesive polymers, poly(acrylic acid), could be identified as a potent inhibitor of proteolytic enzymes. Second, there is increasing evidence that the interaction between various types of bio(muco)adhesive polymers and epithelial cells has direct influence on the permeability of mucosal epithelia. Rather than being just adhesives, mucoadhesive polymers may therefore be considered as a novel class of multifunctional macromolecules with a number of desirable properties for their use as biologically active drug delivery adjuvants. To overcome the problems related to GI mucus and to allow longer lasting fixation within the GI lumen, bioadhesion probably may be better achieved using specific bioadhesive molecules. Ideally, these bind to surface structures of the epithelial cells themselves rather than to mucus by receptor-ligand-like interactions. Such compounds possibly can be found in the future among plant lectins, novel synthetic polymers, and bacterial or viral adhesion/invasion factors. Apart from the plain fixation of drug carriers within the GI lumen, direct bioadhesive contact to the apical cell membrane possibly can be used to induce active transport processes by membrane-derived vesicles (endo- and transcytosis). The nonspecific interaction between epithelia and some mucoadhesive polymers induces a temporary loosening of the tight intercellular junctions, which is suitable for the rapid absorption of smaller peptide drugs along the paracellular pathway. In contrast, specific endo- and transcytosis may ultimately allow the selectively enhanced transport of very large bioactive molecules (polypeptides, polysaccharides, or polynucleotides) or drug carriers across tight clusters of polarized epi- or endothelial cells, whereas the formidable barrier function of such tissues against all other solutes remains intact.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7600586

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  15 in total

1.  Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics.

Authors:  M A Arangoa; M A Campanero; M J Renedo; G Ponchel; J M Irache
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

2.  Mucosal immunogenicity of plant lectins in mice.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 3.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

Review 4.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

Review 5.  From sticky stuff to sweet receptors--achievements, limits and novel approaches to bioadhesion.

Authors:  C M Lehr
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

6.  Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes.

Authors:  Anshuman Shukla; Bhupinder Singh; O P Katare
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Enhanced mucoadhesive capacity of novel co-polymers for oral protein delivery.

Authors:  F Michael Marks; Anthony Lowman
Journal:  J Biomater Sci Polym Ed       Date:  2011-03-04       Impact factor: 3.517

Review 8.  Oral controlled release technology for peptides: status and future prospects.

Authors:  J A Fix
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

9.  Design and in vivo evaluation of an oral delivery system for insulin.

Authors:  M K Marschütz; P Caliceti; A Bernkop-Schnürch
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

10.  Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption.

Authors:  Nicholas A Peppas; J Brock Thomas; James McGinty
Journal:  J Biomater Sci Polym Ed       Date:  2009       Impact factor: 3.517

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.